Nivolumab versus everolimus in advanced renal-cell carcinoma

Robert J. Motzer*, Bernard Escudier, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A. Schutz & 8 others Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li An Xu, Ian M. Waxman, Padmanee Sharma, CheckMate 025 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticle

2902 Citations (Scopus)

Fingerprint Dive into the research topics of 'Nivolumab versus everolimus in advanced renal-cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences